Metastatic colorectal cancer is a largely incurable disease with a pressing need for targeted therapies. A new study sheds light on a surprising interaction between FOXO3a and β-catenin in metastatic colorectal cancer, suggesting new therapeutic avenues for agents targeting the PI3K-AKT pathway (pages 892–901).
